W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

News

13 January, 2026
The Transparency Council meeting 2/2026 on 19 January 2026
read more
12 January, 2026
Recommendation of the President – Paediatric Seravit
read more
12 January, 2026
Recommendation of the President – Xuriden (uridine triacetate)
read more
12 January, 2026
Recommendation of the President – Trulance (plecanatide)
read more
09 January, 2026
Publication AWA
read more
09 January, 2026
The Transparency Council meeting 1/2025 on 12 January 2026
read more
08 January, 2026
Recommendation of the President – Vyloy (zolbetuximab)
read more
05 January, 2026
Recommendation of the President – Carvykti (cyltacabtagen autoleucel)
read more
05 January, 2026
Recommendation of the President – Imfinzi (durvalumab)
read more
05 January, 2026
Recommendation of the President – Oxlumo (lumaziran)
read more
05 January, 2026
Recommendation of the President – Flutixon Nasal (Azelastini hydrochloridum + Fluticasoni propionas)
read more
05 January, 2026
Recommendation of the President – Darzalex (daratumumab)
read more
31 December, 2025
Communication of the meeting of Tariff Council
read more
23 December, 2025
Recommendation of the President – measurement of fibroblast growth factor FGF-23
read more
23 December, 2025
Recommendation of the President – determination of calcium and phosphate concentrations in urine
read more
23 December, 2025
Recommendation of the President – the determination of calprotectin concentration in stool
read more
22 December, 2025
Recommendation of the President – Tremfya (guselkumab)
read more
22 December, 2025
Recommendation of the President – Ibrance (palbociclib)
read more
22 December, 2025
Recommendation of the President – Tremfya (guselkumab)
read more
22 December, 2025
Recommendation of the President – Keytruda (pembrolizumab)
read more
22 December, 2025
Recommendation of the President – Tecentriq (atezolizumab)
read more
22 December, 2025
Recommendation of the President – Tecentriq (atezolizumab)
read more
22 December, 2025
Recommendation of the President – Welireg (belzutifan)
read more
22 December, 2025
Recommendation of the President #HPP #48aa – Prevention of cardiovascular diseases, hypertension, and hypercholesterolemia
read more

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑